One significant area of concern is the corneal endothelium, which plays a crucial role in maintaining corneal transparency and overall eye health. Recent research has focused on understanding how ...

The hiring comes after the company submitted a filing with the Securities and Exchange Commission in January to go public.

In this Healio Video Perspective from Hawaiian Eye 2025, Greg Kunst, CEO of Aurion Biotech, discusses positive phase 1/2 data for the company’s cell therapy for corneal endothelial disease.

Descemet's stripping automated endothelial keratoplasty (DSAEK) is the gold standard for the surgical treatment of corneal endothelial diseases. Following its introduction over the last decade ...

Aurion Biotech, Inc. (Aurion), whose mission is to restore vision to millions of patients with life-changing regenerative ...

In 2022, doctors in Japan performed a transplant of iPS cell-derived corneal endothelial cells iPS cell derived-corneal endothelial cell transplants are injected and take about 20 minutes In Japan ...

AS-OCT improves surgical results in femtosecond laser-assisted corneal surgery such as laser ... period in Descemet stripping automated endothelial keratoplasty cases. Ultra-high-resolution ...

The biotech IPO landscape gains momentum in 2025 as Aurion Biotech, Maze Therapeutics, and Metsera file for offerings. Aurion focuses on regenerative therapies, Maze advances precision medicines for ...